Repros Therapeutics Inc. RPRX is skyrocketing, gaining 32% on the back of news that it submitted data to the FDA for supporting morning assessment of testosterone for men treated with Androxal, which is its drug.
At last check, shares were up 44 cents to $1.85.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
